Old Web
English
Sign In
Acemap
>
authorDetail
>
S. Ignatenko
S. Ignatenko
Charité
Pharmacodynamics
Tolerability
Medicine
Lupus erythematosus
Physical therapy
3
Papers
17
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus:
2018
Lupus
P. Lu
R. Fleischmann
C. Curtis
S. Ignatenko
S.H. Clarke
M. Desai
S. L. Wong
K.M. Grebe
K Black
J. Zeng
J. Stolzenbach
J. Medema
Show All
Source
Cite
Save
Citations (15)
THU0306 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of The BCL-2 Inhibitor Venetoclax (ABT-199) in A Phase 1 Single and Multiple Ascending Dose Study in Female Patients with Systemic Lupus Erythematosus
2016
Annals of the Rheumatic Diseases
P. Lu
R. Fleischmann
C. Curtis
S. Ignatenko
M. Desai
S. L. Wong
K.M. Grebe
J. Zeng
J. Medema
J. Stolzenbach
Show All
Source
Cite
Save
Citations (0)
FRI0315 First Human Dose of the Anti-C5a Receptor-Targeting, Human Monoclonal Antibody NNC0215-0384 in Patients with Rheumatoid Arthritis: A Phase 1, Randomised, Double-Blind, Single-Dose, Dose-Escalation Trial
2014
Annals of the Rheumatic Diseases
Frank Wagner
C.F. Lange
M. Nowak
S. Ignatenko
Show All
Source
Cite
Save
Citations (2)
1